Impact of Stage-Specific Guideline Concordant Treatment in Small Cell Lung Cancer in Victoria, Australia.

ABSTRACT:

Introduction

Lung cancer accounts for 9% of all cancer diagnoses in Australia with a 5-year survival rate of 26%. Small cell lung cancer (SCLC) is a more aggressive subtype of lung cancer, representing 15% of all lung cancer cases and a 5-year survival of 11.1%. This study aims to assess the extent of guideline concordant treatment (GCT) delivery for SCLC in Victoria, identify patient, clinical, and hospital factors influencing GCT receipt, and evaluate its impact on survival.

Methods

Data were obtained from the Victorian Lung Cancer Registry (VLCR) in Victoria, Australia (n = 1769). Descriptive statistics were used to summarie patient and disease characteristics by treatment type, including GCT, non-GCT, and no/declined treatment. Statistical analyses included multiple logi

SUBMITTER: Tissera S 

PROVIDER: S-EPMC12425560 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature